home > news > detailed info

£10.4m Full-Service Contract Signed With Existing Big Pharma Client

Open Oprhan plc

22 August 2022 - Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan, has signed a £10.4m contract with an existing top 5 global pharmaceutical client to manufacture a new batch of H1N1 influenza challenge virus, leveraging off an existing in-house generated challenge model, and to conduct a human challenge trial to test the client’s antiviral product.

hVIVO has world-leading expertise in challenge agent manufacture, with the ability to manufacture specific subtypes of viruses, as well as unrivalled experience in conducting challenge studies. Since the COVID-19 pandemic, the Company has seen an increase in the number of clients looking to test their vaccines and antivirals against specific subtypes of viruses that are circulating in the population or that have the potential to be widely spread. As a result, there is a greater interest in end-to-end human challenge contracts such as this, that include a novel challenge agent manufacture and a challenge study.

The study will evaluate the efficacy profile of the antiviral against the specific influenza subtype, generating data quickly and efficiently. This is the third human challenge contract signed with this client, highlighting the Company’s world leading expertise and the clear benefits of human challenge trials to Big Pharma’s drug development process.

Good Manufacturing Practice ("GMP") compliant virus manufacturing activities will commence immediately and are expected to complete by Q2 2023. Once completed, hVIVO will conduct a Phase 2a double-blinded placebo-controlled human challenge study which is expected to be completed by Q4 2023. hVIVO will recruit healthy volunteers via the Company’s dedicated volunteer recruitment arm, FluCamp. The majority of revenue from the contract is expected to be recognised during 2023.

Yamin ‘Mo’ Khan, Chief Executive Officer of Open Orphan, said: “We’re delighted to be working again with this top 5 global pharmaceutical company to test its antiviral, using a new influenza strain developed by our highly experienced team. This contract is the third challenge study with this client, and our second end-to-end full-service contract overall. Our one-stop shop service offerings from manufacturing bespoke challenge agents to conducting full challenge studies is unique in the market. I am confident, that with our highly qualified teams and their clinical development expertise, we are well placed to address the growing infectious disease and respiratory research markets.

“Influenza poses a serious global health threat, causing an estimated 290,000 - 650,000 deaths per year with significant pandemic potential, and as such, the development of new vaccines and antivirals to fight flu remains vitally important.”

Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, said: “This contract is a strong example of where human challenge studies can provide significant value. These studies can quickly and cost-effectively generate efficacy data for our clients in specific viral subtypes. As illustrated with this contract, our world-class manufacturing capabilities can produce a challenge agent for subtypes that pose a particular global health risk or are already circulating in the population. The resulting data can then indicate whether the candidate is viable for Phase II/III studies, providing substantial time and financial savings compared to traditional field-based studies.”

Interested in becoming a volunteer?

hVIVO recruits many of its volunteers for its challenge study clinical trials through its dedicated volunteer recruitment website, By volunteering to take part in one of our studies in a safe, controlled, clinical environment under expertly supervised conditions you are playing your part to further medical research and help increase the understanding of respiratory illnesses.

For further information please contact:

Open Orphan plc
Yamin Khan, Chief Executive Officer
+353 (0) 1 644 0007

Liberum Capital (Nominated Adviser and Joint Broker)
Ben Cryer/ Edward Mansfield/ Phil Walker/ Will King
+44 (0) 20 3100 2000

finnCap plc (Joint Broker)
Geoff Nash / James Thompson / Richard Chambers
+44 (0) 20 7220 0500 

Davy (Euronext Growth Adviser and Joint Broker)
Anthony Farrell
+353 (0) 1 679 6363

Walbrook PR (Financial PR & IR)
+44 (0)20 7933 8780 or
Stephanie Cuthbert
+44 (0) 7796 794 663
Phillip Marriage
+44 (0) 7867 984 082
Louis Ashe-Jepson
+44 (0) 7747 515 393
phone +44 20 7756 1300
email 21 Plumbers Row, London, E1 1EQ, United Kingdom
Print this page
Send to a friend
News and Press Releases

Datwyler patents sustainable cellulose-based fillers

October 25, 2022 - Datwyler, together with the development partner Empa, has developed and patented an industrial process for surface modification of microfibrillated cellulose (MFC). The modified MFC can be used to substitute petroleum-based aramid fibers as fillers in elastomer compounds. Fillers derived from organic cellulose increase the sustainability of elastomer products.
More info >>

White Papers

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement